drugset / Trial / NCT06984718
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have progressed on the first line treatment of atezolizumab and bevacizumab.
Timeline
- Start
- 2025-06-25
- Primary completion
- 2026-11-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Comparator | Lenvatinib | Small molecule | — | Oral |